YCYuek Ling Chai

Yuek Ling Chai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuek Ling Chai has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Decreased Plasma IGF-1 Is Associated with Cortical Atrophy, but Not Concomitant Cerebrovascular Disease in Alzheimer’s Dementia

    by Amelia T. Y. Yam, Yuek Ling Chai, Saima Hilal, Cai Yuan, Vincent C. T. Mok, Narayanaswamy Venketasubramanian, Boon Yeow Tan, Ming Ann Sim, Mitchell K. P. Lai, Christopher P. Chen, et al.

    Dysregulated insulin signaling in the brain has been linked to cognitive impairment and dementia. Insulin-like growth factor 1 (IGF-1) is a peptide growth hormone crucial for neurogenesis and neuroprotection. Findings regarding potential involvement of IGF-1 in dementia have been conflicting, and the status of IGF-1 in clinical cohorts with Alzheimer’s disease (AD) and concomitant cerebrovascular disease (CeVD) burden is unknown. A Singapore-based memory clinic cohort consisting of 46 non-cognitively impaired (NCI), 101 with cognitive impairment, no dementia (CIND) and 81 AD dementia subjects underwent plasma IGF-1 measurements and neuroimaging assessments for association analyses of peripheral IGF-1 with regional brain volumes, as well as with neuroimaging CeVD markers (lacunes, cerebral microbleeds, white matter hyperintensities). Plasma IGF-1 levels were significantly lower in AD compared to NCI and CIND participants (both p < 0.001). Plasma IGF-1 was significantly associated with smaller hippocampal (p = 0.035), amygdala (p = 0.024), parietal lobe (p = 0.029), and frontal lobe (p = 0.002) volumes. In contrast, plasma IGF-1 did not associate with CeVD markers after covariate adjustments. Our findings suggest that plasma IGF-1 may be a blood-based biomarker for reduced brain volumes, while having no direct role in CeVD pathophysiology.

  • Open Access

    Decreased Plasma IGF-1 Is Associated with Cortical Atrophy, But Not Concomitant Cerebrovascular Disease in Alzheimer’s Dementia

    by Amelia T. Y. Yam, Yuek Ling Chai, Saima Hilal, Cai Yuan, Vincent C. T. Mok, Narayanaswamy Venketasubramanian, Boon Yeow Tan, Ming Ann Sim, Mitchell K. P. Lai, Christopher P. Chen, et al.

    Dysregulated insulin signaling in brain has been linked to cognitive impairment and dementia. Insulin-like growth factor-1 (IGF-1) is a peptide growth hormone crucial for neurogenesis and neuroprotection. Findings regarding potential involvement of IGF-1 in dementia have been conflicting, and the status of IGF-1 in clinical cohorts with Alzheimer’s disease (AD) and concomitant cerebrovascular disease (CeVD) burden is unknown. A Singapore-based memory clinic cohort consisting of 46 non-cognitively impaired (NCI), 101 with cognitive impairment, no dementia (CIND) and 81 AD dementia subjects underwent plasma IGF-1 measurements and neuroimaging assessments for association analyses of peripheral IGF-1 with regional brain volumes, as well as with neuroimaging CeVD markers (lacunes, cerebral microbleeds, white matter hyperintensities). Plasma IGF-1 levels were significantly lower in AD compared to NCI and CIND participants (both p < 0.001). Plasma IGF-1 was significantly associated with smaller hippocampal (p = 0.035), amygdala (p = 0.024), parietal lobe (p = 0.029), and frontal lobe (p = 0.002) volumes. In contrast, plasma IGF-1 did not associate with CeVD markers after covariate adjustments. Our findings suggest that plasma IGF-1 may be a specific blood-based biomarker for neurodegeneration, while having no direct role in CeVD pathophysiology.

  • Open Access

    Fyn-T Kinase Regulates DHA-Induced Pyroptosis in Immortalized Normal Human Astrocytes

    by Ai Ling Cheng, Yuek Ling Chai, Jasinda H. Lee, Clara Y. B. Low, Helen L. Ong, Gavin S. Dawe, Thiruma V. Arumugam, Deron R. Herr, Michelle G. K. Tan, Mitchell K. P. Lai

    Dysregulation of astroglia-mediated neuroinflammation is known to be involved in neurodegenerative diseases. Amongst multiple inflammatory pathways, pyroptosis is characterized by inflammatory cell death following inflammasome activation. Recently, the omega-3 poly-unsaturated fatty acid, DHA, has been identified as a pyroptosis inducer, although the underlying mechanisms remain unclear. In this study, we investigated the role of the alternatively spliced T-isoform of Fyn kinase (FynT) in DHA-induced astroglial pyroptosis. Immortalized normal human astrocytes (iNHA) expressing wild-type FynT (FynT-WT), kinase-dead mutant FynT (FynT-KD), or empty vector (EV) controls were treated with DHA and assessed for pyroptotic activation. We found that DHA-treated FynT-WT cells exhibited significantly reduced cytosolic lactate dehydrogenase release, pyroptotic morphology and markers (cleaved caspase-1 and its substrates, cleaved caspase-3 and gasdermin-D N fragments) compared to either EV or FynT-KD cells. No significant differences in pyroptotic activation were observed between EV and FynT-KD cells. In addition, no differences in immunoreactivities of pro- or anti-apoptotic markers (Bax or Bcl-2) were observed across the DHA-treated cells. In summary, our study postulates a negative regulatory role of FynT kinase in DHA-induced pyroptosis in astrocytes, with implications for further understanding neuroinflammatory mechanisms in neurodegenerative diseases and identification of potential therapeutic targets.

  • Open Access

    Fyn-T Kinase Regulates DHA-Induced Pyroptosis in Immortalized Normal Human Astrocytes

    by Ai Ling Cheng, Yuek Ling Chai, Jasinda H. Lee, Clara Y. B. Low, Helen L. Ong, Gavin S. Dawe, Thiruma V. Arumugam, Deron R. Herr, Michelle G. K. Tan, Mitchell K. P. Lai

    Dysregulation of astroglia-mediated neuroinflammation is known to be involved in neurodegen-erative diseases. Amongst multiple inflammatory pathways, pyroptosis is characterized by in-flammatory cell death following inflammasome activation. Recently, the omega-3 poly-unsaturated fatty acid, DHA, has been identified as a pyroptosis inducer, although the un-derlying mechanisms remain unclear. In this study, we investigated the role of the alternative-ly-spliced T-isoform of Fyn kinase (FynT) in DHA-induced astroglial pyroptosis. Immortalized normal human astrocytes (iNHA) expressing wild-type FynT (FynT-WT), kinase-dead mutant FynT (FynT-KD), or empty vector (EV) controls were treated with DHA and assessed for pyrop-totic activation. We found that DHA-treated FynT-WT cells exhibited significantly reduced cyto-solic lactate dehydrogenase release, pyroptotic morphology and markers (cleaved caspase-1 and its substrates, cleaved caspase-3 and gasdermin-D N fragments) compared to either EV or FynT-KD cells. No significant differences in pyroptotic activation were observed between EV and FynT-KD cells. In addition, no differences in immunoreactivities of pro- or anti-apoptotic markers (Bax or Bcl-2) were observed across the DHA-treated cells. In summary, our study postulates a negative regulatory role of FynT kinase on DHA-induced pyroptosis in astrocytes, with implica-tions for further understanding neuroinflammatory mechanisms in neurodegenerative diseases and identification of potential therapeutic targets.

  • Open Access

    Serum Brevican as a Biomarker of Cerebrovascular Disease in an Elderly Cognitively Impaired Cohort

    by Rachel S. L. Chia, Karolina Minta, Liu-Yun Wu, Kaung H. T. Salai, Yuek Ling Chai, Saima Hilal, Narayanaswamy Venketasubramanian, Christopher P. Chen, Joyce R. Chong, Mitchell K. P. Lai

    In the brain, the extracellular matrix (ECM) composition shapes the neuronal microenvironment and can undergo substantial changes with cerebral pathology. Brevican is integral to the formation of the ECM’s neuroprotective perineuronal nets (PNNs). Decreased brevican levels were reported in vascular dementia (VaD) but not in Alzheimer’s disease (AD). However, the status of brevican in clinical cohorts with high concomitance of AD pathological burden and cerebrovascular disease (CeVD) is unclear. In this study, 32 non-cognitively impaired (NCI), 97 cognitively impaired no dementia (CIND), 46 AD, and 23 VaD participants recruited from memory clinics based in Singapore underwent neuropsychological and neuroimaging assessments, together with measurements of serum brevican. Association analyses were performed between serum brevican and neuroimaging measures of CeVDs, including white matter hyperintensities (WMHs), lacunes, cortical infarcts, and cerebral microbleeds. Using an aggregated score for CeVD burden, only CIND participants showed lower brevican levels with higher CeVD compared to those with lower CeVD burden (p = 0.006). Among the CeVD subtypes assessed, only elevated WMH burden was associated with lower brevican levels (OR = 2.7; 95% CI = 1.3–5.5). Our findings suggest that brevican deficits may play a role in early cerebrovascular damage in participants at risk of developing dementia.


  • Open Access

    Inflammatory panel cytokines are elevated in the neocortex of late-stage Alzheimer’s disease but not Lewy body dementias

    by Yuek Ling Chai, Jasinda H. Lee, Joyce R. Chong, Clive Ballard, Paul T. Francis, Brian K. Kennedy, Thiruma V. Arumugam, Christopher P. Chen, Dag Aarsland, Mitchell K. P. Lai

    Background: Chronically dysregulated neuroinflammation has been implicated in neurodegenerative dementias, with separate studies reporting increased brain levels of inflammatory mediators and gliosis in Alzheimer’s disease (AD) as well as in Lewy body dementias (LBD). However, it is unclear whether the nature and extent of neuroinflammatory responses in LBD are comparable to those in AD. In this study, we performed head-to-head measurements of a panel of cytokines in the post-mortem neocortex of AD versus the two major clinical subtypes of LBD, namely, dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). Methods: Post-mortem tissues from the mid-temporal cortex (Brodmann area 21) of a cohort of neuropathologically well-defined AD, PDD and DLB patients were processed and measured for a comprehensive range of cytokines (IL-1α, IL-1Ra, IL-8, IL-10, IL-12p70, IL-13, IFN-γ, GM-CSF and FGF-2) using a multiplex immunoassay platform. Associations between inflammation markers and neuropathological measures of neuritic plaques, neurofibrillary tangles as well as Lewy bodies were also performed. Results: We found IL-1α, IFN-γ, GM-CSF and IL-13 to be elevated in the mid-temporal cortex of AD patients. In contrast, none of the measured cytokines were significantly altered in either DLB or PDD. Similar cytokine changes were observed in two other neocortical areas of AD patients. Furthermore, increases of IL-1α, IFN-γ, GM-CSF, IL-10 and IL-13 associated with moderate-to-severe neurofibrillary tangle burden, but not with neuritic plaques or Lewy bodies. Our findings of elevated neocortical pro- and anti-inflammatory cytokines in AD, but not in DLB or PDD, suggest that neuroinflammatory responses are strongly linked to neurofibrillary tangle burden, which is higher in AD compared to LBD. In conclusion, neuroinflammation may not play a prominent role in the pathophysiology of late-stage LBD.


  • Open Access

    Elevated Soluble TNF-Receptor 1 in the Serum of Predementia Subjects with Cerebral Small Vessel Disease

    by Kaung H. T. Salai, Liu-Yun Wu, Joyce R. Chong, Yuek Ling Chai, Bibek Gyanwali, Caroline Robert, Saima Hilal, Narayanaswamy Venketasubramanian, Gavin S. Dawe, Christopher P. Chen, et al.

    Tumor necrosis factor-receptor 1 (TNF-R1)-mediated signaling is critical to the regulation of inflammatory responses. TNF-R1 can be proteolytically released into systemic blood circulation in a soluble form (sTNF-R1), where it binds to circulating TNF and functions to attenuate TNF-mediated inflammation. Increases of peripheral sTNF-R1 have been reported in both Alzheimer’s disease (AD) dementia and vascular dementia (VaD). However, the status of sTNF-R1 in predementia subjects (cognitive impairment, no dementia, CIND) is unknown, and putative associations with cerebral small vessel disease (CSVD), as well as with longitudinal changes in cognitive functions are unclear. We measured baseline serum sTNF-R1 in a longitudinally assessed cohort of 93 controls and 103 CIND, along with neuropsychological evaluations and neuroimaging assessments. Serum sTNF-R1 levels were increased in CIND compared with controls (p < 0.001). Higher baseline sTNF-R1 levels were specifically associated with lacunar infarcts (rate ratio = 6.91, 95% CI 3.19–14.96, p < 0.001), as well as lower rates of cognitive decline in the CIND subgroup. Our data suggest that sTNF-R1 interacts with vascular cognitive impairment in a complex manner at predementia stages, with elevated levels associated with more severe CSVD at baseline, but which may subsequently be protective against cognitive decline.


  • Deregulation of CypA‐EMMPRIN pathway in chronic cerebral hypoperfusion: Implication in vascular dementia

    by Yuek Ling Chai, Vismitha Rajeev, Christopher Chen, Thiruma Valavan Arumugam, Mitchell Kim Peng Lai

    Background: Chronic cerebral hypoperfusion (CCH) has been shown to be a key mechanism in vascular cognitive impairment and dementia, leading to various pathologies including blood brain barrier disruption, extracellular matrix dysfunction and inflammation. Cyclophilin A (CypA), an oxidative stress‐induced factor, is secreted into the extracellular space upon stimulation or during cell death and binds to the extracellular matrix metalloproteinase inducer (EMMPRIN). EMMPRIN may in turn activate matrix metalloproteinases (MMPs), leading to downstream inflammatory processes and vascular remodeling. While CypA and EMMPRIN have been studied in animal models of acute ischemic and hemorrhagic stroke [1‐4], their potential involvement in CCH as well as in the clinical setting of VaD awaits investigation.Method: In the first part of the study, the bilateral common carotid artery stenosis (BCAS) model was utilised: microcoils were inserted in both the left and right common carotid arteries for 30 days to induce CCH in male C57BL/6J mice. Sham controls were operated in the same manner without the insertion of microcoils. At the 30‐days endpoint, the animals were euthanized; brain samples were collected and processed for CypA, EMMPRIN, MMP‐2 and MMP‐9 measurement using western blot. In the second part of the study, a cross‐sectional clinical study with 36 non‐cognitive impaired controls and 48 vascular dementia (VaD) subjects was performed. Blood samples were collected, and serum CypA, EMMPRIN, MMP‐2 and MMP‐9 levels were measured using sandwich ELISAs.Result: Lower CypA and higher EMMPRIN levels were found in the brains of BCAS‐induced mice, and in the serum of VaD patients. While MMP‐2 was higher in BCAS‐inducted mice, MMP‐9 was higher in VaD patients. Interestingly in the clinical cohort, higher MMP‐2 was found in the presence of lacunes while MMP‐9 was higher in the presence of white matter hyperintensities, cortical infarct and lacunae, suggesting that the MMPs may be involved in differential pathways despite both being downstream of the CypA‐EMMPRIN pathway.Conclusion: The present study demonstrated that the deregulation of CypA, EMMPRIN and MMPs may play an important role during CCH, and thus be useful clinical biomarkers and potential therapeutic targets in VaD.